OXR

(redirected from Oxaliplatin)
Also found in: Medical, Wikipedia.
AcronymDefinition
OXROxiana Limited (stock symbol)
OXROwens Cross Roads (Owens Cross Roads, Alabama)
OXROxnard / Ventura, CA, USA - Oxnard Airport (Airport Code)
OXROxaliplatin (chemotherapy drug)
OXROfficial Exchange Rate (currency)
OXROffices of Air Force, Army, and Navy Research
References in periodicals archive ?
She was started on combination chemotherapy with oxaliplatin and CAPOX.
This patient received adjuvant chemotherapy composed of oral S-1 75 mg twice daily for 14 days plus oxaliplatin 0.
Following surgery, salvage chemotherapy with capecitabine plus oxaliplatin was administered biweekly (six cycles).
Oxaliplatin injection (100 mg/ml) was purchased from Post Graduate Institute of Medical Education and Research (PGIMER) Chandigarh.
This US FDA approval is based on the company's Phase III trial (RAISE), which compared CYRAMZA plus FOLFIRI to placebo plus FOLFIRI in people with mCRC who had disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.
In the trial, 1,608 patients with resectable stage II or III recta] cancer received neoadjuvant chemoradio-therapy consisting of radiation plus either capecitabine or fluorouracil, each with or without oxaliplatin.
Keywords: Anticancer, Oxaliplatin, DFT, Vibration Frequency, monohydrates.
For oxaliplatin, symptoms may worsen even after discontinuation of therapy and can profoundly affect quality of life and safety (Tofthagen, McAllister, & McMillan, 2011).
However, the relationship between ototoxicity and the newer generation of platinum-derived agents, including oxaliplatin, is not as well established in the literature.
However, executives on a conference call said they expected revenue generated by oxaliplatin to moderate in 2010, anticipating more competition and price erosion.
The influence of KRAS mutation status was investigated in a randomised study that assessed whether the best ORR of cetuximab combined with oxaliplatin, LV and 5-FU (FOLFOX-4) was superior to FOLFOX-4 alone as first-line treatment for mCRC [24].
Victoria Hellberg, of Karolinska Institutet in Stockholm, measured the amount of cisplatin and oxaliplatin that reached the cochlea in guinea pigs following intravenous dosing of each drug.